Phaseline

Targets › LYPLA1

LYPLA1 (Acyl-protein thioesterase 1): drug programs, companies and trials

1 program from 1 company in 5 trials: 3 Phase 1, 1 Phase 3, 1 Phase 2; Gastroenterology, Other, Respiratory; next expected readout Dec 2026.

Acts as an acyl-protein thioesterase. Hydrolyzes fatty acids from S-acylated cysteine residues in proteins such as trimeric G alpha proteins or HRAS. Acts as a palmitoyl thioesterase that catalyzes depalmitoylation of proteins, such as ADRB2, KCNMA1 and SQSTM1. (UniProt, O75608)

Open in Phaseline: the race on LYPLA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Boehringer IngelheimVerducatib (BI 1291583)
Lysophospholipase A1 (LYPLA1) inhibitor
LYPLA1Phase 3Bronchiectasis; HealthyDec 2026

Conditions

Healthy (3) Bronchiectasis (2)

Modalities

small molecule (1)

Companies

Boehringer Ingelheim (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.